NEWTOWN, Pa.--(BUSINESS WIRE)--CollaGenex Pharmaceuticals, Inc. (NASDAQ:CGPI) today announced that the U.S. Patent and Trademark Office (USPTO) has listed the status of its patent application No. 10/117,709, covering Oracea(TM) (the ‘709 Patent Application), as “allowed.” This patent covers the use of sub-antimicrobial tetracyclines for the treatment of acne and acne rosacea, including Oracea. CollaGenex received FDA approval for Oracea on May 26, 2006 and is currently marketing Oracea to the U.S. dermatology community.
